Karyopharm hits record low after endometrial cancer trial miss

Karyopharm Therapeutics

31/07/2026 18:44

** Shares of Karyopharm Therapeutics KPTI.O fall 71.9% to all-time low of $1.97
** Stock falls below its previous 52-week low of $3.65 set in August 2025
** Co said late on Thursday its drug selinexor as a maintenance therapy for advanced or recurrent endometrial cancer missed its main goal of significantly improving progression-free survival, in a late-stage trial
** Patients on selinexor lived a median 12.75 months without disease progression versus 7.43 months on placebo, but the difference was not statistically significant, co said
** Co said it will reduce investment in endometrial cancer and focus more on its myelofibrosis and multiple myeloma programs
** Stock set for its worst trading day on record, if losses hold
** Including session's moves, stock down 73% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))